Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Summary

The objective of this study was to evaluate the therapeutic effect of nafamostat mesilate on patients with severe infection-related coagulation。

Conditions

• Sepsis
• Sepsis-induced Coagulopathy
• Nafamostat Mesilate

Interventions

DRUG

Nafamostat mesilate

Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)

DRUG

5% glucose

Add 50ml of 5% glucose into a 50ml syringe

Sponsors & Collaborators

• Tianjin Third Central Hospital

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Shanxi Provincial People's Hospital

  collaborator OTHER_GOV

• Shanxi Bethune Hospital

  collaborator OTHER

• Hohhot First Hospital

  collaborator UNKNOWN

• The First Bethune Hospital Jilin University

  collaborator UNKNOWN

• Northern Jiangsu People's Hospital

  collaborator OTHER

• The Affiliated Hospital of Nantong University

  collaborator UNKNOWN

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• The First Affiliated Hospital of Suzhou Medical

  collaborator UNKNOWN

• Anhui Provincial Hospita

  collaborator UNKNOWN

• Zhejiang Hospital

  collaborator OTHER

• Zhejiang Provincial People's Hospital

  collaborator OTHER

• The First Affiliated Hospital of Ningbo

  collaborator UNKNOWN

• The First Affiliated Hospital of Wenzhou

  collaborator UNKNOWN

• The Jiangxi Provincial People's Hospital

  collaborator UNKNOWN

• First Affiliated Hospital of Gannan Medical University

  collaborator OTHER

• The Second Affiliated Hospital Xi'an Jiaotong

  collaborator UNKNOWN

• LanZhou University

  collaborator OTHER

• The First Affiliated Hospital of Xinjiang

  collaborator UNKNOWN

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Tongji Medical College of Huazhong University

  collaborator UNKNOWN

• The Second Hospital University of South China

  collaborator OTHER

• The Fourth Affiliated Hospital of China Medical

  collaborator UNKNOWN

• The First Affiliated Hospital of Liaoning

  collaborator UNKNOWN

• Genertec Liaoyou Gem Flower Hospital

  collaborator UNKNOWN

• The Tenth People's Hospital of Shenyang

  collaborator UNKNOWN

• The Sixth People's Hospital of Shenyang

  collaborator OTHER

• Dalian NO.3 People's Hospital

  collaborator UNKNOWN

• Benxi Cental Hospital

  collaborator OTHER

• Liaoyang City Central Hospital

  collaborator UNKNOWN

• Huludao central hospital

  collaborator UNKNOWN

• Xu Li

  lead OTHER

Principal Investigators

• Xu Li, Phd · First Hospital of China Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-10-01

Primary Completion

2026-10-01

Completion

2026-10-01